Podcasts about esbl

 After 2050, more people will die from infection/inflammation than from cancer.The reasons are that through the antibiotic in the food, the bacteria become more and more resistant to the antibiotic, and the overuse of disinfection.The food industry is feeding our animals with an antibiotic since over 50years.Because through antibiotic the animals grow faster and are protected against diseases. In the meantime, a bacteria (Superbug), has developed that can kill everybody and is resistant to the antibiotic or any other common disinfection. If we are under intense stress or our immune system is weak the Superbug has the chance to grow in our body and to kill us!! In the future, antibiotic will not work anymore because we can't increase the doses of antibiotic anymore and the bacteria become resistant to the antibiotic.    For instance, in Germany dying 14,000 People through a Superbug infection which they got in a hospital… Why? The hospitals grow the Superbug like crazy through the overuse of disinfection and antibiotic. The disinfection and antibiotics kill healthy bacteria and give room for the Superbug.And this also comes true for shrimps farms in Asia….Instead to use clean, purified water they put an antibiotic in the water of the shrimps.  In Canada, they have done a survive for the Superbug in shrimps. Even the Canadian government thought it is enough to check for an antibiotic in our food. It is not allowed in Canada to sell food with an antibiotic. The survive checked for the 1.) Superbug,2.) for bacteria that produce ESBL strains to neutralize antibiotic, and3.) for bacteria that are multi-resistance of a different antibiotic.The results have been shocking!The Sciences bought from the supermarket 50 different packages of frozen shrimps mainly from Asia. And then they tested the packages for bacteria. The results:1.) 17% of the packages contained the Superbug even one product was from an organic farm or was a high certified product. 2.) 33% of the boxes contained bacteria that produce ESBL strains to neutralize antibiotic.3.) 88% of the packages contained bacteria that are multi-resistance of a different antibiotic.What is if you think that you don't care because you cook the shrimps?And now comes the problem…When you prepare the shrimps, the Superbugs are all over the place in the kitchen and maybe also on your body and the bodies of your family…. The Superbug can survive for months on the floor or on the spice containers or on the kitchen cabinet….What is if even in your chicken, poultry, pork, seafood, or beef are the Superbug? Imagine you buy seafood, you cut it, and cut the salad with this knife… Then you can have the Superbug in your salad and finally in your gut!  What is if you eat probiotic as fermented vegetables with this salad? Then the probiotic can kill the Superbug! And this I proof again and again that you have to eat probiotic every day!!!!!!My Video: How the antibiotic can kill us?! https://youtu.be/x-fLN8HqUGo My Audio: https://divinesuccess.net/wp-content/uploads/2021/Podcast.B/How-the-antibiotic-can-kill-us.mp3

Dr. Becca Bruning, Infectious Diseases Pharmacy Specialist at the Moffitt Cancer and Research Institute in Tampa, FL, takes a deep dive into the subject of resistance mechanisms for specific gram negative bacteria. Dr. Bruning begins her talk by discussing the primary resistance mechanisms, including porin channels, efflux pumps, and other target sites. Extended spectrum beta-lactamases (ESBLs) are next covered, including typical bacterial species, identification techniques, ESBL testing, and the use of Piperacillin-tazobactam and carbapenems. Next, Dr. Bruning mentions AmpC-type resistance, and identifies the “HECKYES” bacteria. Pharmacokinetic and phamacdynamic considerations are explored, and specific antimicrobial agents are discussed. Lastly, Dr. Bruning covers the use of carbapenemase testing including the modified hodge test and the Carba-R test.

In this episode, Martin talks to Cansu Cimen, a researcher at University Hospitals Groningen in the Netherlands, about a recent paper that documents an outbreak and in particular the critical role of next-generation sequencing (NGS) in tracking and controlling the transmission of MDROs via contaminated duodenoscopes. Focusing on an outbreak linked to ESBL-producing Citrobacter freundii and Klebsiella pneumoniae after endoscopic retrograde cholangiopancreatography (ERCP), standard culture methods failed to detect contamination. After many negative cultures using established methods, destructive dismantling of the implicated scope revealed contamination on hard-to-clean components, highlighting NGS as an effective tool for identifying pathogen transmission pathways. Cimen C, Bathoorn E, Loeve AJ, Fliss M, Berends MS, Nagengast WB, et al. Uncovering the spread of drug-resistant bacteria through next-generation sequencing based surveillance: transmission of extended-spectrum beta-lactamase-producing Enterobacterales by a contaminated duodenoscope. Antimicrob Resist Infect Control 2024;13(1):31. https://doi.org/10.1186/s13756-024-01386-5. Download the paper here

In this episode, Martin talks to Cansu Cimen, a researcher at University Hospitals Groningen in the Netherlands, about a recent paper that documents an outbreak and in particular the critical role of next-generation sequencing (NGS) in tracking and controlling the transmission of MDROs via contaminated duodenoscopes. Focusing on an outbreak linked to ESBL-producing Citrobacter freundii and Klebsiella pneumoniae after endoscopic retrograde cholangiopancreatography (ERCP), standard culture methods failed to detect contamination. After many negative cultures using established methods, destructive dismantling of the implicated scope revealed contamination on hard-to-clean components, highlighting NGS as an effective tool for identifying pathogen transmission pathways. Cimen C, Bathoorn E, Loeve AJ, Fliss M, Berends MS, Nagengast WB, et al. Uncovering the spread of drug-resistant bacteria through next-generation sequencing based surveillance: transmission of extended-spectrum beta-lactamase-producing Enterobacterales by a contaminated duodenoscope. Antimicrob Resist Infect Control 2024;13(1):31. https://doi.org/10.1186/s13756-024-01386-5. Download the paper here

In dieser Folgen wird es „nerdig“: Wir besprechen anhand der IDSA Guidance on the Treatment of Antimicrobial Resitant Gram-Negativ Infections die multiresistenten gramnegativen Erreger. In dieser Folge – Teil 1 dieses Themas- geht es um ESBL (extended-spectrum β-lactamases ), AmpC Betalaktamasen und CRE (Carbapenem-resistant Enterobacterales). Wir erklären die unterscheidlichen Resistenzmechanismen, diskutieren deren Folgen und Therapiemöglichkeiten. … „Infektiopod #86: Multiresistente gramnegative Erreger – Teil 1“ weiterlesen

TWiM explores evolution and host adaptation of Pseudomonas infections of plants, and the impact of COVID-19 on ESBL-producing E. coli on urinary tract and blood infections. Hosts: Vincent Racaniello and Michael Schmidt. Become a patron of TWiM. Links for this episode Evolution and host adaptation of Pseudomonas (Science) Type III secretion system, infection by injection (Nat Comm) Demographic inference with skyline plots (Peer J) Skyline plots (Taming the Beast) Panaroo, a bacterial genome analysis pipeline (Wellcome Sanger Inst) Impact of COVID-19 on ESBL-producing E. coli infections (Antimicro Resist Inf Control) Take the TWiM Listener survey! Music used on TWiM is composed and performed by Ronald Jenkees and used with permission. Send your microbiology questions and comments (email or recorded audio) to twim@microbe.tv

Research in MLS? In this episode Grace Leu-Burke, director of the Medical Laboratory Sciences (MLS) program at the University of Alaska in Anchorage, returns to the podcast. She talks to Luis about the research program the MLS students are involved in. They culture scat from moose, bears, and geese, perform identification and susceptibility testing, and more. What kind of antimicrobial resistance is found in this sample population? Tune in to learn more about this research. Link to JAM meeting registration: https://www.labjam.org/event/cc75ef76-49db-4175-8440-d194382bcf05/websitePage:d132f4da-b01b-4c7c-9ea8-5866e2b0f8caTitle of Grace's Talk: “Emerging Antimicrobial Resistance, A One Health Model”Thursday July 11th at 9:30amQuestions? Feedback? Send those to letstalkmicro@outlook.comWant to support the podcast? Here's how:Venmo: https://venmo.com/u/letstalkmicroBuy me a Ko-fi: https://ko-fi.com/letstalkmicro

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2

Velkommen tilbake til podkast med Elin og Marthe bak instagramkontoen og hjemmesiden Smittevernsnerdene! I denne episoden besvares spørsmål fra publikum og dere lyttere har virkelig sendt inn gode og relevante spørsmål, som alltid! For hvordan skal man egentlig forholde seg til jobb og kollegaer i helsevesenet hvis man selv er helsepersonell med ESBL? Hva er de vanligste feilene som helsepersonell gjør når det kommer til smittevern og hvilken type smitte er “verst”? Dette er episode 2 av 2 med Smittevernsnerdene. Vask henda og kos dere med nok en lærerik episode! Den del gjerne begge episodene videre til kollegaer og medstudenter. Stay tuned!Smittevernsnerdenes hjemmeside: https://smittevernsnerdene.com/Smittevernsnerdenes epost: Smittevernsnerdene@gmail.comPodkastens instagram: Hjelp_jeg_er_sykepleierProgramleder: Helene Dahl KarlsenProdusenter: Helene Dahl Karlsen & Fanny NorbyeJingler og musikk: Philip ØstliKontakt: hjelp.jeg.er.sykepleier@gmail.comFor annonsering: elin@modernemedia.noLogo: Lisa Marie Eri og Christine SamuelsenUkens annonnsør og personlig anbefaling er boken “Bare” en sykepleier: Boka til Celine fås kjøpt hos blant annet Norli, Ark og Akademika og finnes også som lydbok hos blant annet Nextstory og Storytel. Dette er den perfekte julegaven til noen du skulle ønske hadde “litt” mer kunnskap om hvordan sykepleieres hverdag faktisk er, i tiden vi lever i. Jeg vil faktisk anbefale boken til absolutt alle, uansett om man kjenner innsiden av norsk helsevesenet eller ei. “Bare” en sykepleier er både morsom, rørende og seriøs. Den har blitt en soleklar favoritt på min bokhylle og jeg mener helt seriøst at boka burde vært pensum. God lesing!

Synes du også resistens er vanskelig? Fatt mot og bli med oss i Pestpodden på en reise gjennom resistensen! I anledning Antibiotikauken 2023 har vi nemlig to spesialepisoder. I del èn får du en enkel intro til antimikrobiell resistens - mens i del to intervjuer vi en av verdens fremste eksperter og forskere på feltet; Adam Roberts. Gled deg!Referanser:1.Barlow M, Hall BG. Phylogenetic analysis shows that the OXA beta-lactamase genes have been on plasmids for millions of years. J Mol Evol. 2002;55(3):314-21.2.D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, et al. Antibiotic resistance is ancient. Nature. 2011;477(7365):457-61.3. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176-87.4.Woerther PL, Andremont A, Kantele A. Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community level. J Travel Med. 2017;24(suppl_1):S29-s34.5.NORM/NORM-VET 2022. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø / Oslo 2023. ISSN:1502-2307 (print) / 1890-9965 (electronic). . 2022.7. https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=48.Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including: Mechanisms of β-lactam resistanceEffect of resistance mechanism on susceptibility to antipseudomonal agent2023 IDSA guidance recommendations Activity against newer antipseudomonal β-lactams in the United StatesThe latest clinical data by antimicrobial regimen:              - Ceftolozane/tazobactam              - Ceftazidime/avibactam              - Imipenem/cilastatin/relebactam              - CefiderocolApplying antimicrobial stewardship principlesProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP  Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland  School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical Center|Baltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine  Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139Link to full program: https://bit.ly/40HyvPy 

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems Program Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/40Mmicz

Welcome to Part 2 of this pair of episodes on management of antimicrobial resistant Gram-negative infections!! Drs. Hawra Al-Lawati and Pranita Tamma walk through the alphabet soup of CRE with 2 mini-cases. Don't miss the prior episode (Febrile #76) for more on AmpC and ESBL!You can find the most updated 2023 IDSA Guidance at this link: https://www.idsociety.org/practice-guideline/amr-guidanceEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com

Welcome to Part 1 of this pair of episodes on management of antimicrobial resistant Gram-negative infections!! Drs. Hawra Al-Lawati and Pranita Tamma walk through the alphabet soup of AmpC and ESBL with 3 mini-casesYou can find the most updated 2023 IDSA Guidance at this link: https://www.idsociety.org/practice-guideline/amr-guidanceEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com

No episódio da vez Klinger e Jordan vão discutir um tema muito pedido pelos nossos ouvintes: mecanismos de resistência. Nesse episódio em especial, falaremos de ampC e ESBL: o que é, marcadores no antibiograma e como tratar. Manda para o seu amigo que precisa aprender também! Vem com a gente.

Sarah A. Chase, PharmD identifies the most common ESBL-producing bacteria and common ESBL resistance genes, recognizes the use and limitations in using phenotypic and genotypic data to identify potential ESBL-E organisms and discusses clinical trial data and IDSA guidance to assist in the selection of appropriate antimicrobials for the treatment of ESBL-E infections . For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter! You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Join Jame as he talks through the ESCMID and IDSA treatment of Multi Drug Resistant Gram negative guidelines/guidance. Callum listens and occasionally asks a question! Jame is so passionate on this subject that we have split the episode into two parts.ECDC guidelines·          https://onlinelibrary.wiley.com/doi/full/10.1111/j.1469-0691.2011.03570.x·          https://www.ecdc.europa.eu/en/news-events/multidrug-resistant-extensively-drug-resistant-and-pandrug-resistant-bacteria-0 Canadian guidelines·          https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/ccdr-volume-44-1-january-4-2018/ccdr-rmtc-44-1-ar07-eng.pdf IDSA-       https://www.idsociety.org/practice-guideline/amr-guidance-2.0/#  Comparison of IDSA and ESCMID-       https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00054-4/fulltext -       https://amr.solutions/2019/01/13/categories-of-resistance-mdr-xdr-pdr-udr-and-new-dtr/

Join Jame and Callum as they discussion all things beta lactamase including ESBL, AmpC and Carbapenemases.  We talk through classification systems, patterns of resistance and some methods of detection.  Some resources we found helpful:Summary of beta lactamase classification:https://microbeonline.com/betalactamase-classification/Summary of AmpC:https://www.idstewardship.com/heck-yes-get-amped-updates-ampc-harboring-bacteria/EUCAST detection of resistance:https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdfUK SMI on Carbapenemases:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1080594/B_60i3.1.pdfMore in depth AmpC:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763639/Send comments suggestions and feedback to idiotspodcasting@gmail.com

第434回　シリーズ「薬剤耐性菌について」ESBLについて 出演：菅井 基行（国立感染症研究所 薬剤耐性研究センター長） 番組HPはこちら↓ http://www.radionikkei.jp/kansenyobo/ #感染症  #薬剤耐性菌　 See omnystudio.com/listener for privacy information.

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:Epidemiology and burden of nosocomial bacterial pneumoniaPatient-specific risk factors for MDR pathogensImproving outcomes with the use of antibiogramsRecommended empiric therapy for clinically suspected VABPAntimicrobial resistance in HABP/VABPAlgorithms for gram-negative organism antibiotic-susceptibility testingUsing rapid diagnostic tests for HABP/VABPNew antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:ASPECT-NP: ceftolozane/tazobactam vs meropenemREPROVE: ceftazidime/avibactam vs meropenemRESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenemRESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactamAPEKS-NP: cefiderocol vs meropenemCREDIBLE-CR: cefiderocol vs best available therapyProgram Director:Keith S. Kaye, MD, MPHChiefDivision of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyFaculty:Lilian Abbo, MD, FIDSAAssociate Chief Medical Officer in Infectious DiseasesJackson Health SystemProfessor of Infectious DiseasesDepartment of Medicine & Miami Transplant InstituteUniversity of Miami Miller School of MedicineMiami, FloridaJason M. Pogue, PharmDClinical ProfessorDepartment of Clinical PharmacyUniversity of Michigan College of PharmacyInfectious Diseases Clinical PharmacistMichigan MedicineAnn Arbor, MichiganContent based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.Follow along with a downloadable slideset at:https://bit.ly/3CEop6hLink to full program https://bit.ly/3i781lf

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd), authors of the IDSA Guidance on gram-negative resistance, join Dr. Erin McCreary (@ErinMcCreary) for this exquisitely good episode to discuss the soon-to-be-updated guidance on treatment of ESBL producers, CRE producers, and difficult to treat (DTR) Pseudomonas. Learn more about the Society of Infectious Diseases Pharmacists: Website: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress - PubMed (nih.gov) CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales - PubMed (nih.gov) Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) - PubMed (nih.gov) Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections - PubMed (nih.gov)

The best basketball sim league playoff bout to start get hype --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/biggzlife/support

Episode Notes This episode features Dr. Elizabeth Dodds Ashley and Dr. Shaefer Spires. The article discussed in this podcast is available here: https://doi.org/10.1093/cid/ciaa1479. For more information about the Duke Antimicrobial Stewardship Outreach Network (DASON), please visit: https://dason.medicine.duke.edu.

From generating 150 liters-worth of E. coli to the first X-ray crystallography of an ESBL, Drs. Robert Bonomo, Ryan Shields (@ryankshields), and Erin McCreary (@ErinMcCreary) take a deep dive into beta-lactamases like AmpCs, KPCs, and more.

We're all racing neck and neck against antimicrobial resistance - trying to preserve antibiotics for use in the most critical situations. This equine specialist pinpoints actions horse owners and veterinarians can take to minimize spread of resistant pathogens in horse populations and facilities. With fewer anti-microbials in our equine veterinary toolkit, it is essential that we learn all we can about how antimicrobial resistant pathogens travel between horses and their handlers. Without being able to identify and track antibiotic resistant bacteria, we are left in the dark when we try to adjust our management of our animals to minimize disease and to save these valuable medications for situations where they are absolutely necessary. Dr. Maud de Lagarde is a researcher and diplomate of the American College of Veterinary Internal Medicine who studies the movement of antimicrobial resistant genes in bacterial populations that affect horses in both Quebec and France. She is specifically interested in their route of dissemination to develop strategies to prevent antimicrobial resistance, and her work highlights some interesting intervention points for horse owners and veterinarians alike. Links of Interest:  Prevalence, risk factors, and characterization of multidrug resistant and extended spectrum β-lactamase/AmpC β-lactamase producing Escherichia coli in healthy horses in France in 2015  (de Lagarde M, Larrieu C, Praud K, Schouler C, Doublet B, Sallé G, Fairbrother JM, Arsenault J. Prevalence, risk factors, and characterization of multidrug resistant and extended spectrum β-lactamase/AmpC β-lactamase producing Escherichia coli in healthy horses in France in 2015. J Vet Intern Med. 2019 Mar;33(2):902-911. doi: 10.1111/jvim.15415. Epub 2019 Jan 15. PMID: 30648296; PMCID: PMC6430864.) Prevalence, Risk Factors, and Characterization of Multidrug Resistant and ESBL/AmpC Producing Escherichia coli in Healthy Horses in Quebec, Canada, in 2015–2016 (de Lagarde M, Fairbrother JM, Arsenault J. Prevalence, Risk Factors, and Characterization of Multidrug Resistant and ESBL/AmpC Producing Escherichia coli in Healthy Horses in Quebec, Canada, in 2015-2016. Animals (Basel). 2020;10(3):523. Published 2020 Mar 20. doi:10.3390/ani10030523) Spread of multidrug-resistant IncHI1 plasmids carrying ESBL gene bla CTX-M-1 and metabolism operon of prebiotic oligosaccharides in commensal Escherichia coli from healthy horses, France (Maud de Lagarde, Caroline Larrieu, Karine Praud, Nathalie Lallier, Angélina Trotereau, Guillaume Sallé, John M. Fairbrother, Catherine Schouler, Benoît Doublet, Spread of multidrug-resistant IncHI1 plasmids carrying ESBL gene blaCTX-M-1 and metabolism operon of prebiotic oligosaccharides in commensal Escherichia coli from healthy horses, France, International Journal of Antimicrobial Agents, Volume 55, Issue 6, 2020, 105936, ISSN 0924-8579) 

Nous sommes tous engagés dans une course contre la résistance aux antibiotiques et nous essayons de préserver l'efficacité de ces médicaments pour pouvoir continuer à les utiliser dans les situations les plus critiques. Cette spécialiste en médecine équine propose aux propriétaires de chevaux et aux vétérinaires équins des mesures qui peuvent être utilisées pour réduire la propagation de bactéries pathogènes résistantes au sein de la population équine et dans les écuries. Étant donné la réduction du nombre d'antibiotiques disponibles dans la trousse médicale des vétérinaires équins, il est essentiel que ces derniers aient accès à un maximum de connaissances concernant la façon dont les bactéries pathogènes résistantes aux antibiotiques peuvent se transmettre entre les chevaux et leurs propriétaires. Si les vétérinaires équins ne savent pas comment identifier et suivre les mouvements des bactéries résistantes aux antibiotiques, il leur est difficile d'adapter la gestion de leurs cas pour réduire le risque de maladies et réserver ces médicaments importants aux situations pour lesquelles ils sont absolument nécessaires. Dre Maud de Lagarde est chercheure et diplomée du Collège américain de médecine interne vétérinaire (ACVIM). Elle étudie les mouvements des gènes de résistance aux antibiotiques dans les populations bactériennes retrouvées chez les chevaux au Québec et en France. Elle s'intéresse particulièrement à la façon dont ces gènes se propagent afin de développer des stratégies de prévention de la résistance. Son travail souligne des possibilité d'interventions concrètes pour les propriétaires de chevaux et leurs vétérinaires. Liens d'intérêt: Prevalence, risk factors, and characterization of multidrug resistant and extended spectrum β-lactamase/AmpC β-lactamase producing Escherichia coli in healthy horses in France in 2015  (de Lagarde M, Larrieu C, Praud K, Schouler C, Doublet B, Sallé G, Fairbrother JM, Arsenault J. Prevalence, risk factors, and characterization of multidrug resistant and extended spectrum β-lactamase/AmpC β-lactamase producing Escherichia coli in healthy horses in France in 2015. J Vet Intern Med. 2019 Mar;33(2):902-911. doi: 10.1111/jvim.15415. Epub 2019 Jan 15. PMID: 30648296; PMCID: PMC6430864.) Prevalence, Risk Factors, and Characterization of Multidrug Resistant and ESBL/AmpC Producing Escherichia coli in Healthy Horses in Quebec, Canada, in 2015–2016 (de Lagarde M, Fairbrother JM, Arsenault J. Prevalence, Risk Factors, and Characterization of Multidrug Resistant and ESBL/AmpC Producing Escherichia coli in Healthy Horses in Quebec, Canada, in 2015-2016. Animals (Basel). 2020;10(3):523. Published 2020 Mar 20. doi:10.3390/ani10030523) Spread of multidrug-resistant IncHI1 plasmids carrying ESBL gene bla CTX-M-1 and metabolism operon of prebiotic oligosaccharides in commensal Escherichia coli from healthy horses, France (Maud de Lagarde, Caroline Larrieu, Karine Praud, Nathalie Lallier, Angélina Trotereau, Guillaume Sallé, John M. Fairbrother, Catherine Schouler, Benoît Doublet, Spread of multidrug-resistant IncHI1 plasmids carrying ESBL gene blaCTX-M-1 and metabolism operon of prebiotic oligosaccharides in commensal Escherichia coli from healthy horses, France, International Journal of Antimicrobial Agents, Volume 55, Issue 6, 2020, 105936, ISSN 0924-8579) 

It's the JournalFeed Podcast for the week of Jun 21-25, 2021. We cover the benefit of scribes, choosing alternative antibiotics in penicillin allergic patients, how to prevent post-LP headache, treating highly resistant gram-negatives, and more problems with the HEART score.

It’s the JournalFeed Podcast for the week of Dec 14-18, 2020. We cover antibiotics for nasal packing, the myth of “Type L” COVID-19 ARDS phenotype, long vs ultralong ultrasound-guided IVs, the rise of ESBL UTIs in the ED, and the HaVOC RCT on haloperidol vs ondansetron for cannabis hyperemesis.

Korvpallipodcasti "Pihtas Põhjas" 35.osa külaline on praegune Audentese spordigümnaasiumi direktor Priit Ilver. Läbi ja lõhki korvpalli taustaga, isa Tiit tulnud Tartu Riikliku Ülikooli eest mängides neljal korral Eesti meistriks (andmed ESBL-ist). Priit sai tiitleid kolm, neist esimese keskkoolipoisina. Oli üks esimesi, kes põrutas Eestist USA-sse ülikoolikossu mängima. Tuli tagasi ja sai rahapakkidega vastu pead. Kohe nii, et valus hakkas... Audentese osas räägime dilemmast. Miks ei taha treenerid Audentese spordigümnaasiumisse tööle minna? Kandideerimisavaldusi laekub väga visalt. Hea tasemega õpilased, head baasid, aga treenerid ei taha tulla. Midagi justkui ei klapi. Vestlust veab Ivar Jurtšenko.

Show notes at pharmacyjoe.com/episode472. In this episode, I ll discuss an article about using piperacillin-tazobactam for the treatment of ESBL pyelonephritis. The post 472: Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by ESBL Producing Organisms? appeared first on Pharmacy Joe.

Join us with our guest: Maureen Spencer, RN, M.Ed., CIC joining us to discuss an array of important topics: 1. Overuse and inappropriate prescribing of antibiotics worldwide is leading to the global healthcare issue of antibiotic resistance. 2. Empiric antibiotics are used consistently in healthcare when infection is suspected 3. Empiric antibiotics are prescribed to cover gram positive, gram negative and yeast infections until the final lab result is available 4. Overuse of antibiotics adversely effect the normal flora and microbiome in the body depleting colonies of bacteria that are necessary for digestion and protection. 5. When the microbiome is depleted other resistant species overgrow on the skin and in the systems of the body, especially the gut. 6. Multiple Drug Resistant organisms MDRO include MRSA, VRE, ESBL and CRE that will grow in patients who have been on antibiotics AND MUCH MORE.

Join us with our guest: Maureen Spencer, RN, M.Ed., CIC joining us to discuss an array of important topics: 1. Overuse and inappropriate prescribing of antibiotics worldwide is leading to the global healthcare issue of antibiotic resistance. 2. Empiric antibiotics are used consistently in healthcare when infection is suspected 3. Empiric antibiotics are prescribed to cover gram positive, gram negative and yeast infections until the final lab result is available 4. Overuse of antibiotics adversely effect the normal flora and microbiome in the body depleting colonies of bacteria that are necessary for digestion and protection. 5. When the microbiome is depleted other resistant species overgrow on the skin and in the systems of the body, especially the gut. 6. Multiple Drug Resistant organisms MDRO include MRSA, VRE, ESBL and CRE that will grow in patients who have been on antibiotics AND MUCH MORE.

Dr. Bachmeier presents an up-to-date review of newer-generation antimicrobials designed to be effective against infections with multiple drug-resistant pathogens. He first reviews the different types of extended-spectrum beta-lactamase (ESBL) resistance. He then discusses the significance of Carbapenemase-producing enterobacteriaceae and ESBL producing E coli, Klebsiella pneumonia, and Pseudomonas aeruginosa strains. Such organisms have become increased threats to our patients over the last two decades while new drug approvals have dwindled. Dr. Bachmeier reviews Ceftolozane-tazobactam, Ceftazidime-avibactam and their current indications. He then reviews Meropenem-vaborbactam and its utility in the treatment of Klebsiella pneumonia carbabenemase (KPC) infections. He then discusses imipenem-relebactam and its advantages in the treatment of MDR gram-negative infections. Lastly, he reviews plazomycin, eravacycline, and Cefiderocol.

Join the EMGuideWire crew once again for this month's series on Sepsis in honor of Sepsis Awareness month. Episode 3 will cover antibiotic use and selection. Antibiotics for Sepsis Take a history and perform a chart biopsy first! Consider past infections, bug susceptibilities, healthcare acquired vs. community acquired infection, foreign travel, and comorbidities.  Always check local antibiogram and prior culture results. Septic shock - Start broad spectrum antibiotics within 1 hour. Stable patient - find the source! UA, CXR, and a good skin exam are fast and can help guide antibiotic choice. Remember some patients need surgical management!  Antibiotic choice in septic shock. 1st agent - Piperacillin/Tazobactam (covers GP/GN + Pseudo)  2nd agent - Choose based on patient characteristics Ceftriaxone - simple community acquired infections. Vancomycin - covers MRSA. Meropenem - use for patients with a hx of ESBL. Flagyl + cefepime/meropenem - Use for intra-abdominal infections. Clindamycin - Useful for skin infections (toxin suppression).  Cefazolin - IV line infections, endocarditis, soft tissue infections w/o MRSA (covers MSSA, GAS, GBS).  Summarized by: Travis Barlock, MD PGY-1 References: Alam N et al. 2018. Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial. The Lancet. Respiratory Medicine. 6(1): 40-50.  Dellinger RP, Levy MM, Rhodes A, et al. 2017. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2016. Critical Care Medicine. 44(3):486-552.

Durante el programa de la semana pasada (EP 164) hablamos de las betalactamasas de espectro extendido y comentamos de donde habían surgido, como se definen, y cual es la epidemiologia asociada a las mismas. En el programa de esta semana (EP 165) hablamos del  diagnostico y opciones de tratamiento de la infecciones causadas por enterobacterias productoras de betalactamasas de espectro extendido.   Referencias:   David M Livermore y colaboradores. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?  J Antimicrob Chemother 2012; 67:1569-1577 Gutierrez-Gutierrez y J Rodriguez-Bano.Current options for the treatment of infections due to extended- spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clin Microbiol Infect 2019; 25 (8): 932-942. Vardakas KZ y colaboradores. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67(12):2793-80 Palacios-Baena ZR y colaboradores. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clin Infect Dis 2017; 65 (10) 1615-1623. Belen Gutieerez-Gutierrez y colaboradores. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother 2016; 71: 1672-1680. Harris PNA y colaboradores. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone ResistanceA Randomized Clinical Trial. JAMA 2018; 320 (10): 984-994.   La Frase de la Semana:   Esta semana tomamos la frase de la periodista y escritora española Rosa Montero nacida en Madrid el 3 de Enero de 1951. Como nota interesante para los infectologos, a causa de la tuberculosis estuvo desde los cinco años hasta los 9 recluida en casa dedicándose  a leer y escribir La Frase dice:   “La vida es un pequeño espacio de luz entre dos nostalgias: la de lo que aun no has vivido y al de lo que ya no vas a poder vivir. Y el momento justo de la acción es tan confuso, tan resbaladizo y tan efímero que lo desperdicias mirando con aturdimiento alrededor”  

En el episodio de esta semana iniciamos una serie de episodios relacionados con la resistencia bacteriana. Esta semana empezamos con beta-lactamasas de espectro extendido.  Referencias:  Yohei Doi y colaboradores. The ecology of extended-spectrum b-lactamases (ESBLs) in the developed world. Journal of Travel Medicine, 2017, Vol. 24, Suppl 1. S44-S51. Patricia A. Bradford. Extended-Spectrum

In this episode I cover antibiotics.If you want to follow along with written notes on bacteria go to zerotofinals.com/antibiotics/ or find the infectious diseases section in the Zero to Finals medicine book.This episode covers the mechanism of action, local resistance, guidelines, penicillin allergy and coverage of antibiotic. The audio in the episode was expertly edited by Harry Watchman.

In this episode I cover bacteria.If you want to follow along with written notes on bacteria go to zerotofinals.com/bacteria/ or find the respiratory section in the Zero to Finals medicine book.This episode covers the anatomy and physiology, classification, gram staining and individual types of bacteria. The audio in the episode was expertly edited by Harry Watchman.

Protect Your Kids at Petting Zoos From Drug Resistant BacteriaShow Notes:A new study finds petting zoos can be breeding grounds for drug resistant bacteria (MDR) including e coli. These bacteria can place anyone touching animals at risk, particularly young children.This study was done by researchers from Ariel University in Israel. They choose eight petting zoos at random, collecting fecal matter samples and swabs from fur, skin, and feathers from 228 animals representing 42 species. Of particular interest were two bacteria types, extended spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacteriaceae (AmpC-E). These bacteria are known to be highly resistant to antibiotics.About 12% of animals were colonized with at least one of the bacterial strains. Researchers discovered 35 bacterial species including two strains of e coli. E coli can cause serious The authors found that nearly 1 in 8 animals (12%) were found to be colonized with at least one of the two antibiotic-resistant bacterial strains, with 35 different recovered species of bacteria. A quarter of animals that tested positive for drug-resistant bacteria had more than one bacterial strain, including two e. coli strains. E coli can cause serious diarrhea and other infections.According to researchers, children are at elevated risk of illness from these pathogens. One of the Researchers Speaks:Professor Shiri Navon-Venezia at Ariel University, one of the researchers, comments,“Our findings demonstrate that animals in petting zoos can result in shedding and transmission of MDR pathogens that may cause illness for human visitors, even when the animals appear healthy,”She continues (note: the professor was identified as "he" in the audio. My apology for the error),“We recognize the high educational and emotional value of petting zoos for children, therefore, we strongly recommend that petting zoo management teams implement a strict hygiene and infection control policy, together with rationalized antibiotic policy, in order to reduce the risk of transmission between animals and visitors.”Common Sense PrecautionsIf you take your kids or grandkids to petting zoos, apply these common sense precautions:- No food or drink consumption by kids until after they have visited and touched all of the animals AND HAVE WASHED THEIR HANDS AND EXPOSED SKIN COMPLETELY.- Don’t let them touch any objects that will be touched by other people during the time they’re interacting with petting zoo animals.- If there is any indication an animal is being treated with antibiotics, don’t let children touch or come near that animal.- As soon as possible, change children’s clothing. Place the clothing items directly in the washer and wash the clothes in hot water and dry with high heat.- Ensure YOU wash your hands and exposed skin after touching clothes worn by children at the petting zoo.For more, “Safe Living Today” episodes, visit us at www.SafeLivingToday.com.Sources and Resources“Petting Zoos May Be Crawling With Drug-Resistant Bacteria, Putting Kids At Risk”. https://www.studyfinds.org/petting-zoos-multi-drug-resistant-bacteria/.European Society of Clinical Microbiology and Infectious Diseases. "Petting zoos could potentially transmit highly virulent drug-resistant bacteria to visitors." ScienceDaily. ScienceDaily, 14 April 2019. www.sciencedaily.com/releases/2019/04/190414111457.htm

Protect Your Kids at Petting Zoos From Drug Resistant BacteriaShow Notes:A new study finds petting zoos can be breeding grounds for drug resistant bacteria (MDR) including e coli. These bacteria can place anyone touching animals at risk, particularly young children.This study was done by researchers from Ariel University in Israel. They choose eight petting zoos at random, collecting fecal matter samples and swabs from fur, skin, and feathers from 228 animals representing 42 species. Of particular interest were two bacteria types, extended spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacteriaceae (AmpC-E). These bacteria are known to be highly resistant to antibiotics.About 12% of animals were colonized with at least one of the bacterial strains. Researchers discovered 35 bacterial species including two strains of e coli. E coli can cause serious The authors found that nearly 1 in 8 animals (12%) were found to be colonized with at least one of the two antibiotic-resistant bacterial strains, with 35 different recovered species of bacteria. A quarter of animals that tested positive for drug-resistant bacteria had more than one bacterial strain, including two e. coli strains. E coli can cause serious diarrhea and other infections.According to researchers, children are at elevated risk of illness from these pathogens. One of the Researchers Speaks:Professor Shiri Navon-Venezia at Ariel University, one of the researchers, comments,“Our findings demonstrate that animals in petting zoos can result in shedding and transmission of MDR pathogens that may cause illness for human visitors, even when the animals appear healthy,”She continues (note: the professor was identified as "he" in the audio. My apology for the error),“We recognize the high educational and emotional value of petting zoos for children, therefore, we strongly recommend that petting zoo management teams implement a strict hygiene and infection control policy, together with rationalized antibiotic policy, in order to reduce the risk of transmission between animals and visitors.”Common Sense PrecautionsIf you take your kids or grandkids to petting zoos, apply these common sense precautions:- No food or drink consumption by kids until after they have visited and touched all of the animals AND HAVE WASHED THEIR HANDS AND EXPOSED SKIN COMPLETELY.- Don’t let them touch any objects that will be touched by other people during the time they’re interacting with petting zoo animals.- If there is any indication an animal is being treated with antibiotics, don’t let children touch or come near that animal.- As soon as possible, change children’s clothing. Place the clothing items directly in the washer and wash the clothes in hot water and dry with high heat.- Ensure YOU wash your hands and exposed skin after touching clothes worn by children at the petting zoo.For more, “Safe Living Today” episodes, visit us at www.SafeLivingToday.com.Sources and Resources“Petting Zoos May Be Crawling With Drug-Resistant Bacteria, Putting Kids At Risk”. https://www.studyfinds.org/petting-zoos-multi-drug-resistant-bacteria/.European Society of Clinical Microbiology and Infectious Diseases. "Petting zoos could potentially transmit highly virulent drug-resistant bacteria to visitors." ScienceDaily. ScienceDaily, 14 April 2019. www.sciencedaily.com/releases/2019/04/190414111457.htm

Show notes at pharmacyjoe.com/episode340. In this episode I ll: 1. Discuss an article about using piperacillin-tazobactam in ESBL infection. 2. Answer the drug information question “Should adjunctive dexamethasone be given to adults with bacterial meningitis if they have already received at least 1 dose of antibiotics?” 3. Share a tip for responding to inpatient medical emergencies. The post 340: Can piperacillin-tazobactam be used in ESBL, adjunctive dexamethasone in bacterial meningitis, and a tip for responding to inpatient medical emergencies appeared first on Pharmacy Joe.

Aunque en el tratamiento de infecciones causadas por microorganismos productores de beta-lactamasa de espectro extendido (BLEE) se favorece tradicionalmente el uso de carbapenemicos existe la esperanza que otros antibióticos puedan ser efectivos. De eso se trata el Estudio Merino, cuyos resultados fueron dados a conocer recientemente en Europa.  Referencias:    Vardakas KZ y colaboradores. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother  Dec 2012. Shiber S y colaboradores. b-Lactam/b-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. J Antmicrob Chemother Jan 2015. Son SK y colaboradores. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother May 28, 2018. Combo antibiotic found inferior for MDR bloodstream infections   La Frase de la Semana: La tomamos de Aristóteles.Vivió en la Antigua Grecia entre el 384 y el 322 a.C. pero su pensamiento ha influido de manera directa a occidente por más de dos milenios. Pero de todo lo que escribió, solo nos ha llegado una pequeña parte. Escribió más de 200 tratados de diferentes temas, que comprendía, además de la filosofía, las matemáticas, la política, la retórica o incluso la biología.   “Cualquiera puede enfadarse, eso es algo muy sencillo. Pero enfadarse con la persona adecuada, en el grado exacto, en el momento oportuno, con el propósito justo y del modo correcto. Eso, ciertamente, no resulta tan sencillo”  

El programa de esta semana es variado. Empezamos por discutir las implicaciones de la bacteriemia por bacilos Gram-negativos resistentes en pacientes con trasplantes de medula ósea. Posteriormente comentamos un articulo sobre el tiempo apropiado de tratamiento en bacteriemia por bacilos Gram-negativos. También comentamos los beneficios del tratamiento combinado vs. el tratamiento simple con oseltamivir en la infección por Influenza. Finalmente hablamos sobre neumonía adquirida en la comunidad, sobre fosfomicina, y nitrofurantoina.   Referencias:   Diana Averbuch y colaboradores. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Diseases 2017.   Julio A. Ramirez y colaboradores. Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis 2017.   Darunee Chotiprasitsakul  y colaboradores Comparing the Outcomes of Adults With  Enterobacteriaceae Bacteremia Receiving Short-Course  Versus Prolonged-Course Antibiotic therapy in a  Multicenter, Propensity Score–Matched Cohort . Clin Infect Dis 2017   John H Beigel y colaboradores. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. Dec 2017.   Fiona Fransen y colaboradores. Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. Dec 2017.   Fiona Fransen y colaboradores.  Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. J Antimicrob Chemother. December 2007     La Frase de la Semana:  La tomamos del poeta Chileno Pablo Neruda. Pablo Neruda Era el seudónimo y, más tarde, el nombre legal del poeta, diplomático y político chileno Ricardo Eliécer Neftalí Reyes Basoalto (12 de julio de 1904 - 23 de septiembre de 1973). Derivó su seudónimo del poeta checo Jan Neruda. Pablo Neruda ganó el Premio Nobel de Literatura en 1971  “Algún día en cualquier parte, en cualquier lugar indefectiblemente te encontrarás a ti mismo, y ésa, sólo ésa, puede ser la más feliz o la más amarga de tus horas”.      

Kirurgia, syöpähoidot ja elinsiirrot ryytyvät, jos bakteereja karaistaan vielä paremmin antibiootteja kestäviksi. Kaikissa näissä tarvitaan antibiootteja tulehdusten varalta. Nyt bakteerit totutetaan antibiootteihin, kun turhia kuureja syödään jatkuvasti. Matkailija kerää mukaansa superbakteereita, jos ottaa antibiootteja riskialueilla. Kuuri tappaa lälläribakteerit ja tekee tilaa lääkkeitä kestäville superbakteereille. Antibiootteja nappaava matkailija valikoi riskialueelta tuliaisiksi kaikkein vastustuskykyisimmät ESBL-superbakteerit. Ja resistenssiongelma pahenee. Studiossa Leena Mattila sekä professorit Anu Kantele ja Pentti Huovinen.

Sat, 18 Jul 2015 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/18586/ https://edoc.ub.uni-muenchen.de/18586/1/Gerhofer_Carolin_E.pdf Gerhofer, Carolin

Shiga toxin producing E. coli (STEC) can occur either as part of the normal intestinal gut flora or as pathogenic agents in animals and humans causing serious disease in humans. In the present study we determined the frequencies of resistance against 14 different antimicrobial agents of in total 235 STEC isolates from farm cattles, wild ruminants and food products. This susceptibility testing was performed using broth microdilution method. Overall, the most frequent resistances were detected against streptomycin, sulfonamides, and tetracycline. Furthermore, 30 of the 36 resistant isolates detected in this study were multi drug resistant against two or more antimicrobial agents. Another focus of this study was the detection of potential ESBL producing isolates, which show resistance to the enlarged spectrum of β‐lactam antibiotics such as cephalosporins of the 3rd and 4th generation. Therefore, all STEC isolates were examined both phenotypically and genotypically using microdilution method and PCR, respectively. Performing a sequential analysis the majority (8/10) of those isolates were non‐ESBL blaTEM‐1. However, using microdilution method detectably minor susceptibility to 3rd and 4th generation cephalo‐sporins in five (2.1%) out of the 235 studied STEC isolates was observed. Overall, antimicrobial susceptibility of STEC isolates could be detected in isolates from domestic ruminants as well as in a very small proportion of wild ruminant isolates.

Laboratoriumscreening Enterobacteriacae op aanwezigheid Extended Spectrum Betalactamese species (ESBL), afdeling Medische Microbiologie, laboratorium, microbiologie, enterobacteriën, ESBL

Laboratoriumscreening Enterobacteriacae op aanwezigheid Extended Spectrum Betalactamese species (ESBL), afdeling Medische Microbiologie, laboratorium, microbiologie, enterobacteriën, ESBL